[1] 甲状腺癌诊疗规范 (2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1): 1-15. [2] 王宇, 田文, 嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识 (2020版)[J]. 中国实用外科杂志, 2020, 40(9): 1012-1020. [3] Barletta JA, Nosé V, Sadow PM.Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations[J]. Endocr Pathol, 2021, 32(1): 35-43. [4] Pizzato M, Li M, Vignat J, Laversanne M, Singh D, La Vecchia C, Vaccarella S.The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020[J]. Lancet Diabetes Endocrinol, 2022, 10(4): 264-272. [5] Angelousi A, Hayes AR, Chatzellis E, et al.Metastatic medullary thyroid carcinoma: a new way forward[J]. Endocr Relat Cancer, 2022, 29(7): R85-R103. [6] 刘文, 程若川, 苏艳军, 等. 甲状腺乳头状癌中央区淋巴结转移危险因素研究 (附3273例回顾性分析)[J]. 中国实用外科杂志, 2018, 38(3): 316-321. [7] 孙荣华, 潘先均, 苏新良, 等. 甲状腺乳头状癌颈部淋巴结转移特点及清扫策略[J]. 中国癌症杂志, 2016, 26(1): 80-87. [8] 傅迎霞, 张羽, 朱红, 等. 甲状腺乳头状癌颈侧区淋巴结转移的危险因素及影像诊断价值评估[J]. 医学影像学杂志, 2021, 31(8): 1287-1292. [9] Wang Y, Deng C, Shu X, et al.Risk Factors and a Prediction Model of Lateral Lymph Node Metastasis in CN0 Papillary Thyroid Carcinoma Patients With 1-2 Central Lymph Node Metastases[J]. Front Endocrinol (Lausanne), 2021, 12: 716728. [10] Weber T, Schilling T, Frank-Raue K, et al.Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinoma[J]. Surgery, 2002, 130(6): 1044-1049. [11] 陈晖, 方少兵, 刘金煌. 甲状腺髓样癌的超声图像特征及与甲状腺乳头状癌的超声鉴别诊断分析[J]. 中国医学工程, 2020, 28(4): 86-88. [12] Kuo EJ, Sho S, Li N, et al.Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma[J]. JAMA Surg, 2018, 153(1): 52-59. [13] 闫维, 姜涛, 郑晓. 甲状腺乳头状癌颈淋巴结转移特点及危险因素分析[J]. 现代肿瘤医学, 2017, 25(5): 709-712. [14] 郭丰丽, 李利娟,阮先辉,等.甲状腺髓样癌复发或转移的影响因素[J]. 中华医学杂志, 2022,102(48): 3849-3855. |